Abstract:BACKGROUND & OBJECTIVE:Increasing evidences showed that circulating tumor metastasis related factors could be detected, and it is related to tumor stage, and prognosis. This study was to investigate the correlation of serum vascular endothelial growth factor (sVEGF), CD44 standard (CD44s), and matrix metalloproteinase-3 (MMP-3) level to the clinical outcomes in nasopharyngeal carcinoma (NPC)patients.METHODS:Forty-six NPC patients without metastasis, 20 NPC patients with local recurrence and/or distant metastasis,and 28 healthy controls entered this study. Serum VEGF, CD44s, and MMP-3 protein were quantitatively analyzed by enzyme-link immunosorbent assay (ELISA).RESULTS:The mean level of sVEGF in metastatic NPC was (791.7+/-560.5) ng/L, which was significantly higher than that in NPC patients without metastasis [(429.0+/-249.7) ng/L], and healthy controls [(424.6+/-197.1) ng/L], whereas there was no significant difference between NPC patients without metastasis and healthy controls. In primary NPC patients, sVEGF level in NPC of stage T4 were significantly higher than those in NPC of stage T1-T3. Moreover, 2-year disease-free survival rate in patients with sVEGF level of more than 600 ng/L was significantly lower than that in patients with sVEGF Level of less than 600 ng/L (37.5% vs 83.9%). The serum level of MMP-3 in NPC patients with metastasis [(28.8+/-15.5)microg/L] was significantly higher than that in patients without metastasis [(19.8+/-11.6) microg/L], and healthy controls [(16.2+/-11.1) microg/L], but there was no significant difference between NPC patients without metastasis and healthy controls. Though the serum level of CD44s in NPC patients (including patients with or without metastasis) was higher than that in healthy controls, there was no significant difference between NPC patients with and without metastasis. No correlation was observed between serum MMP-3, CD44s level and clinical outcomes of NPC.CONCLUSION:Our results indicate that when the sVEGF level are >or= 800 ng/L and/or serum MMP-3 level >or= 30 microg/L in NPC patients, local recurrence or distant metastasis would occur. In primary NPC patients without metastasis, sVEGF level is correlate with primary tumor progression, moreover, sVEGF level of >or= 600 ng/L before treatment predicate lower 2-year disease-free survival rate.

Dynamic of Serum Levels of VEGF in Nasopharyngeal Patients in Course of Radiotherapy

[The Study of Vascular Endothelial Growth Factor in Nasopharyngeal Carcinoma Patients Before and after Radiotherapy].

Elevation of Serum Vascular Endothelial Growth Factor in Male Patients with Metastatic Nasopharyngeal Carcinoma

Prospective Validation of the Prognostic Value of Elevated Serum Vascular Endothelial Growth Factor in Patients with Nasopharyngeal Carcinoma: More Distant Metastases and Shorter Overall Survival after Treatment

The Relationship Between the Serum VEGF Expression and PET/CT Findings of the TNM-Staging of the Nasopharyngeal Carcinoma

Serum proteomics identify potential biomarkers for nasopharyngeal carcinoma sensitivity to radiotherapy.

[Clinical Significance of Quantitative Analysis of Serum VEGF, CD44s, and MMP-3 Protein in Nasopharyngeal Carcinoma].

Changes of serum concentrations of neopterin in patients with nasopharyngeal carcinoma

Changes in C-Kit Expression Levels During the Course of Radiation Therapy for Nasopharyngeal Carcinoma

Study on the radiotherapy effect and serum neutral granulocyte lymphocyte ratio and inflammatory factor expression of nasopharyngeal carcinoma

Parametric Contrast-Enhanced Ultrasound As an Early Predictor of Radiation-Based Therapeutic Response for Lymph Node Metastases of Nasopharyngeal Carcinoma.

[Expression Clinical Significance of Nm23-H1 and Vessel Endothelium Growth Factor Protein in Nasopharyngeal Carcinoma].

[Clinical value of vascular endothelial growth factor detection in forecasting distant metastasis risk of nasopharyngeal carcinoma]

Serum Angiogenin Concentration in Nasopharyngeal Carcinoma Patients and Its Clinical Significance

[Serial (18)F-FDG PET-CT Imaging During Radiotherapy for Nasopharyngeal Carcinoma: a Prospective Clinical Study].

Correlation Between the Kinetics of Plasma EBV DNA Levels and Clinical Response During Treatment in Patients with Nasopharyngeal Carcinoma

Quantitative Assessment of Vasculature with DCE-MRI in Nasopharyngeal Carcinomas Following Radiotherapy and Its Value for Efficacy Evaluation

Effect of concurrent chemoradiotherapy on serum vascular endothelial growth factor in esophageal squamous cell carcinoma patients--a report of 43 cases]

[Enhancement of Radio Sensitivity in Nasopharyngeal Cancer Cells by the Own Regulation of VEGF Expression after Adenovirus-E1a Gene Therapy].

Combination of Pigment Epithelium‐derived Factor with Radiotherapy Enhances the Antitumor Effects on Nasopharyngeal Carcinoma by Downregulating Vascular Endothelial Growth Factor Expression and Angiogenesis

Epression and Significance of VEGF-C,COX-2 and VEGFR-3 in Nasopharyngeal Carcinoma